Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBX-115 in Advanced Solid Tumors
NCT06060613Phase 2Recruiting
- Sponsor
- Obsidian Therapeutics
- Start
- Oct 2023
- Primary completion
- Jun 2029
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of OBX-115 in melanoma and non-small cell lung cancer (NSCLC), sponsored by Obsidian Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days and Objective Response Rate at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
OBX-115
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06060613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060613.